Intech Investment Management LLC Makes New Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Intech Investment Management LLC bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 78,071 shares of the biopharmaceutical company’s stock, valued at approximately $834,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Xponance Inc. increased its stake in Amicus Therapeutics by 5.3% in the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 936 shares during the last quarter. Hazlett Burt & Watson Inc. increased its stake in shares of Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the last quarter. Arizona State Retirement System increased its stake in shares of Amicus Therapeutics by 2.6% in the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after purchasing an additional 1,577 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Amicus Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,884 shares in the last quarter. Finally, OLD Second National Bank of Aurora bought a new stake in shares of Amicus Therapeutics during the 3rd quarter worth $26,000.

Amicus Therapeutics Stock Up 0.9 %

Shares of FOLD opened at $9.96 on Friday. The stock’s 50-day moving average price is $10.75 and its two-hundred day moving average price is $10.59. Amicus Therapeutics, Inc. has a 12 month low of $9.02 and a 12 month high of $14.57. The company has a market capitalization of $2.98 billion, a PE ratio of -29.29 and a beta of 0.68. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at $9,398,532.40. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 30,401 shares of company stock worth $352,038 over the last ninety days. 2.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on FOLD shares. Cantor Fitzgerald boosted their target price on Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Bank of America raised their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Finally, Guggenheim raised their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.63.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.